Wellcome Trust Sanger Institute Uses Affymetrix (Santa Clara, California) Technology to Reveal Changes in 800 Cancer Cell Lines

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that the Wellcome Trust Sanger Institute has developed a catalog of structural genomic changes in almost 800 cancer cell lines using the company’s Genome-Wide Human SNP Array 6.0. Cancer cell lines are invaluable reagents in analyzing the molecular biology of the disease as well as important tools in developing new healing methods.

Back to news